Paradice Investment Management LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 956,407 shares of the medical device company's stock after buying an additional 52,966 shares during the quarter. Tandem Diabetes Care makes up about 6.8% of Paradice Investment Management LLC's portfolio, making the stock its 4th biggest position. Paradice Investment Management LLC owned about 1.46% of Tandem Diabetes Care worth $34,450,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Bellevue Group AG raised its position in Tandem Diabetes Care by 19.9% in the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company's stock valued at $78,496,000 after buying an additional 307,624 shares during the last quarter. JPMorgan Chase & Co. raised its position in Tandem Diabetes Care by 134.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after buying an additional 113,355 shares during the last quarter. MetLife Investment Management LLC raised its position in Tandem Diabetes Care by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 37,422 shares of the medical device company's stock valued at $1,587,000 after buying an additional 21,086 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in Tandem Diabetes Care by 368.5% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 26,125 shares of the medical device company's stock valued at $1,108,000 after buying an additional 20,549 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Tandem Diabetes Care by 32.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 272,097 shares of the medical device company's stock valued at $11,540,000 after buying an additional 66,687 shares during the last quarter.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on TNDM shares. Canaccord Genuity Group dropped their target price on Tandem Diabetes Care from $57.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, November 7th. Robert W. Baird lowered their price target on Tandem Diabetes Care from $39.00 to $37.00 and set a "neutral" rating on the stock in a research report on Thursday, November 7th. Morgan Stanley raised Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and set a $45.00 price target on the stock in a research report on Monday, December 2nd. Citigroup lowered their price target on Tandem Diabetes Care from $57.00 to $50.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Finally, Sanford C. Bernstein started coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They set an "outperform" rating and a $42.00 price target on the stock. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $53.81.
Read Our Latest Stock Report on Tandem Diabetes Care
Tandem Diabetes Care Stock Performance
TNDM traded down $1.12 during trading on Friday, hitting $31.00. The stock had a trading volume of 906,169 shares, compared to its average volume of 937,531. The company has a 50 day moving average price of $35.48 and a 200-day moving average price of $36.75. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -16.06 and a beta of 1.32. Tandem Diabetes Care, Inc. has a one year low of $24.42 and a one year high of $53.69. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.
About Tandem Diabetes Care
(
Free Report)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
See Also
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
